Ankyra Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.ankyratx.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Not Applicable
1 (33.3%)A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
Not Applicable
Not yet recruiting
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)Renal TransplantSolid TumorSolid Tumor Cancer
- Interventions
- Drug: tolododekin alfa
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Ankyra Therapeutics, Inc
- Target Recruit Count
- 20
- Registration Number
- NCT07100925
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Phase 1
Not yet recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: tolododekin alfa
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Ankyra Therapeutics, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT07027514
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorCutaneous TumorSubcutaneous TumorMalignant Solid TumorSolid TumorMetastatic Solid TumorMetastasis to Soft TissueNon Small Cell Lung CancerCutaneous Squamous Cell Carcinoma
- Interventions
- Drug: tolododekin alfa
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Ankyra Therapeutics, Inc
- Target Recruit Count
- 97
- Registration Number
- NCT06171750
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Providence Cancer Institute, Portland, Oregon, United States
News
No news found